Vendor, Ames, IA
Neovaxsyn Inc.
UEI EHMTBALCKFE8, CAGE 7RK00
4 awards and $2,300,000 obligated between April 17, 2024 and June 25, 2026, 100% under full and open competition, against 3.5 offers on average where reported. 3 of the awards trace back to a SAM.gov solicitation on this site.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $2,300,000 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 4 |
| Small Business Set Aside - Total | 4 |
| Definitive Contract | 4 |
Hear when Neovaxsyn Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
None of Neovaxsyn Inc.'s contracts with a published end date ends in the next 19 months.
Competes with
Vendors selling research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology) to National Institutes of Health, by dollars.
| Leidos Biomedical Research Inc.Frederick, MD | $2,186,369,442 |
| Westat, Inc.Rockville, MD | $760,724,225 |
| Technical Resources International, Inc.Bethesda, MD | $196,391,189 |
| Duke UniversityDurham, NC | $158,758,507 |
| MriglobalKansas City, MO | $117,921,746 |
| The Johns Hopkins UniversityBaltimore, MD | $100,932,043 |
Solicitations it won
SAM.gov opportunities whose award USAspending attributes to this vendor.
- Nanovaccine for Eliciting Broadly Neutralizing Antibodies against HIV-1
National Institutes of Health, National Institutes of Health Niaid
Award noticeSmall businessNAICS 541715Ames, IA75N93024C00019Awarded to Neovaxsyn Inc. for $2,000,000
Posted Jan 14, 20252 publications
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93024C00019Definitive Contract, June 25, 2024, Full and Open Competition After Exclusion of Sources, 2 offersSolicitation | National Institutes of Health NiaidNational Institutes of Health | Nanovaccine for Eliciting Bnabs Against HIV-1NAICS 541715, PSC AN12 | $2,000,000 |
| 75N93024C00050Definitive Contract, July 30, 2024, Full and Open Competition After Exclusion of Sources, 7 offersSolicitation | National Institutes of Health NiaidNational Institutes of Health | Development of a Next-Generation Immunoprevention Platform Against HIV-1NAICS 541715, PSC AN12 | $300,000 |
| 75N93021C00026Definitive Contract, April 17, 2024, Full and Open Competition After Exclusion of Sources, 4 offers | National Institutes of Health NiaidNational Institutes of Health | Nanovaccine for Eliciting 10e8-Like Bnabs Against HIV-1NAICS 541715, PSC AN12 | $0 |
| 75N93022C00029Definitive Contract, June 10, 2024, Full and Open Competition After Exclusion of Sources, 1 offers | National Institutes of Health NiaidNational Institutes of Health | SBIR Phase INAICS 541715, PSC AN11 | $0 |
- Places of performance
- Iowa
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied ResearchAN11 Health R&D Services; Health Care Services; Basic Research
- Transactions
- 9 across 4 awards